Home  »  Industry   »  Which institution holds the most shares in Editas ...

Which institution holds the most shares in Editas Medicine Inc. (EDIT)

Editas Medicine Inc. (NASDAQ: EDIT) is -60.94% lower on its value in year-to-date trading and has touched a low of $9.59 and a high of $34.27 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The EDIT stock was last observed hovering at around $10.46 in the last trading session, with the day’s loss setting it -0.09%.

Currently trading at $10.37, the stock is -12.75% and -16.19% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.17 million and changing -0.86% at the moment leaves the stock -28.38% off its SMA200. EDIT registered -69.51% loss for a year compared to 6-month gain of 2.07%.

China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored

The stock witnessed a -10.91% loss in the last 1 month and extending the period to 3 months gives it a -36.26%, and is -15.35% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.00% over the week and 7.40% over the month.

Editas Medicine Inc. (EDIT) has around 264 employees, a market worth around $716.98M and $25.60M in sales. Distance from 52-week low is 8.13% and -69.74% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.90%).

Editas Medicine Inc. (EDIT) Analyst Forecasts

Editas Medicine Inc. is expected to release its quarterly report on 03/07/2023.The EPS is expected to shrink by -43.90% this year

Editas Medicine Inc. (EDIT) Top Institutional Holders

The shares outstanding are 68.74M, and float is at 68.43M with Short Float at 26.99%.

Editas Medicine Inc. (EDIT) Insider Activity

A total of 8 insider transactions have happened at Editas Medicine Inc. (EDIT) in the last six months, with sales accounting for 6 and purchases happening 2 times. The most recent transaction is an insider sale by Eaton Bruce, the company’s EVP, CHIEF BUSINESS OFFICER. SEC filings show that Eaton Bruce sold 289 shares of the company’s common stock on Nov 08 at a price of $11.02 per share for a total of $3185.0. Following the sale, the insider now owns 64738.0 shares.

Editas Medicine Inc. disclosed in a document filed with the SEC on Sep 06 that ROBERTSON MICHELLE (EVP, CHIEF FINANCIAL OFFICER) sold a total of 192 shares of the company’s common stock. The trade occurred on Sep 06 and was made at $15.01 per share for $2882.0. Following the transaction, the insider now directly holds 82475.0 shares of the EDIT stock.

Still, SEC filings show that on Sep 06, Eaton Bruce (EVP, CHIEF BUSINESS OFFICER) disposed off 101 shares at an average price of $15.01 for $1516.0. The insider now directly holds 65,027 shares of Editas Medicine Inc. (EDIT).

Editas Medicine Inc. (EDIT): Who are the competitors?

The company’s main competitors (and peers) include Molecular Templates Inc. (MTEM) that is trading -85.92% down over the past 12 months.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Receive Best Stock To Trade Before The Opening Bell

 

 

100% Free. Stop Anytime. No Spam

111365

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.